XML 79 R61.htm IDEA: XBRL DOCUMENT v3.19.3
Acquisitions - Purchase price as of the Regentys acquisition (Details) - USD ($)
Jul. 31, 2019
Jan. 07, 2019
Nov. 27, 2018
Jul. 31, 2018
Dec. 28, 2017
Jul. 31, 2017
Cash and cash equivalents $ 298,485 $ 61,857   $ 1,046,365   $ 2,879,165
Other current assets 275,731 13,138   96,251    
Property and equipment, net 499,993 444   31,536    
Accounts payable and accrued liabilities (19,055,822) (1,181,920)   (11,044,774)    
Notes payable (8,368,379) (639,009)   (320,000)    
Loans from related parties   (16,506)        
Deferred tax liability (889,782) (889,782)   (1,040,173)    
In-process research & development   3,510,680        
Note receivable from Generex   14,345,205        
Redeemable non-controlling interest 4,073,898 (4,073,898)   0    
Non-controlling interest 16,974,439 (9,870,762)   (5,576,272)    
Cash paid prior to the time of closing   0        
Total Fair Value of Assets Acquired   1,259,447        
Cash paid prior to the time of closing   400,000        
Goodwill $ 38,297,573 13,485,758   $ 0 $ 0  
Allocation Adjustments            
Cash and cash equivalents   0 $ (400,000)      
Other current assets   20,543 0      
Property and equipment, net   0        
Accounts payable and accrued liabilities   (307,495)        
Notes payable   29,685        
Loans from related parties   (399,999)        
Deferred tax liability   30,320 397,513      
In-process research & development   (119,630) (1,521,000)      
Note receivable from Generex   (2,791) 0      
Non-controlling interest   (2,791) 0      
Cash paid prior to the time of closing   400,000 400,000      
Total Fair Value of Assets Acquired   (751,613) (1,383,485)      
Cash paid prior to the time of closing   0 0      
Note receivable from Generex     0      
Goodwill   748,823 1,383,485      
Revised Allocation            
Cash and cash equivalents   61,857 208,419      
Other current assets   33,591 37,950      
Property and equipment, net   444        
Accounts payable and accrued liabilities   (1,488,870)        
Notes payable   (609,324)        
Loans from related parties   (416,505)        
Deferred tax liability   (859,462) (642,660)      
In-process research & development   3,391,050 2,459,000      
Note receivable from Generex   14,345,414 11,472,663      
Redeemable non-controlling interest   (4,073,898)        
Non-controlling interest   (9,870,762) (11,999,559)      
Cash paid prior to the time of closing   400,000 400,000      
Total Fair Value of Assets Acquired   907,833 2,461,440      
Cash paid prior to the time of closing   400,000 400,000      
Note receivable from Generex     11,472,664      
Goodwill   $ 13,834,581 $ 9,411,224